ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine

(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine

Request For Quotation
(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine Basic information
Product Name:(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine
Synonyms:(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine;EOS-61289;HMPL-523;Pyrido[3,4-b]pyrazin-5-amine, 7-[4-[1-(methylsulfonyl)-4-piperidinyl]phenyl]-N-[(2S)-2-morpholinylmethyl]-;HMPL 523|||HMPL523|||HMPL-523;Sovleplenib, 10 mM in DMSO;HM-0523;HMPL-523 acetate
CAS:1415792-84-5
MF:C24H30N6O3S
MW:482.6
EINECS:
Product Categories:
Mol File:1415792-84-5.mol
(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine Structure
(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine Chemical Properties
Boiling point 701.3±70.0 °C(Predicted)
density 1.37±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
pka8.54±0.40(Predicted)
form Solid
color Light green to green
InChIKeyNJIAKNWTIVDSDA-FQEVSTJZSA-N
SMILESC12=C(NC[C@H]3OCCNC3)N=C(C3=CC=C(C4CCN(S(C)(=O)=O)CC4)C=C3)C=C1N=CC=N2
Safety Information
MSDS Information
(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine Usage And Synthesis
UsesSovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP)[1].
in vivo

Sovleplenib (HMPL-523) shows anti-tumor activity in vivo. Sovleplenib (100 mg/kg) inhibits tumor growth in REC-1 subcutaneous xenograft model[1].
Sovleplenib (HMPL-523; 100 mg/kg; daily oral administration) shows potent anti-tumor activity in B cell lymphoma REC-1 (TGI: 59%) in Syk dependent xenograft models [2].

Animal Model:Balb/c nude mice bearing subcutaneously implanted REC-1 cells or intravenously injected BA/F3 cells or BA/F3 TEL-SYK cells[1]
Dosage:10 and 100 mg/kg
Administration:q.d.; for 8 days
Result:Inhibited tumor growth in REC-1 subcutaneous xenograft model at 100 mg/kg.
References[1] Su WG, et al. Preparation of pyridopyrazine derivatives for use as Syk inhibitors. WO2012167733 A1.
[2] Na Yang, et al. HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo. Blood (2016) 128 (22): 3970.
(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine Preparation Products And Raw materials
Tag:(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine(1415792-84-5) Related Product Information
Gusacitinib PRT-060318 5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide 7H-Thieno[3,2-b]pyran-7-one, 3-[4-[[4-[4-(1-azetidinylmethyl)-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]phenyl]-5-(4-morpholinyl)- Chemerin15 5-Pyrimidinecarboxamide, 2-[[(3R,4R)-3-aminotetrahydro-2H-pyran-4-yl]amino]-4-[(4-methylphenyl)amino]-, hydrochloride (1:2)